All News

Cohort study (n 186) from NYC shows that patients with COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressives https://t.co/TMCcKbns0f

Links:

https://bit.ly/34Tlur7

Dr. John Cush RheumNow ( View Tweet)

Nov 03, 2020

RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0

Links:

https://bit.ly/3kQbxQI

Dr. John Cush RheumNow ( View Tweet)

Oct 31, 2020

Links:

https://bit.ly/2WXXRIy

Dr. John Cush RheumNow ( View Tweet)

Oct 31, 2020

Links:

https://bit.ly/3oN9K10

Dr. John Cush RheumNow ( View Tweet)

Oct 31, 2020

QD104 - You Are So Not Disabled QD Clinic - Lessons from the clinic Grappling with Disability Letter Requests Features Dr. Jack Cush https://t.co/Vg5i9rHyKN

Links:

https://bit.ly/2HRhQ8r

Dr. John Cush RheumNow ( View Tweet)

Oct 30, 2020

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

d Jack Cush, MD

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article

Autoantibodies can be found in COVID-19 ptas (including ANA, RF, -RNP centromere and antibobides against phospholipids (3/52), prothrombin (2/52), and c-ANCA (2/52)) (THIS IS A PREPRINT) https://t.co/kN6hVMiNt3 https://t.co/4yNJJhOxXP

Links:

https://nyti.ms/2HHHQ5O

Dr. John Cush RheumNow ( View Tweet)

Oct 28, 2020

Links:

https://bit.ly/31Rbe0z

Dr. John Cush RheumNow ( View Tweet)

Oct 28, 2020

ACTIV-1 run by the ⁦@NIH⁩ will test rheum drugs infliximab and abatacept in COVID-19. This is great news. https://t.co/IITzGTuxEC

Links:

NIH begins large clinical trial to test immune modulators for treatment of COVI…

Dr Philip Robinson philipcrobinson ( View Tweet)

Oct 28, 2020

FDA Hearing on COVID-19 Vaccines

Save

d Jack Cush, MD

Oct 23, 2020

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

Read Article

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Save

d Jack Cush, MD

Oct 23, 2020

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article

Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr

Links:

https://bit.ly/2HtYwxg

Dr. John Cush RheumNow ( View Tweet)

Oct 23, 2020

Remdesivir FDA Approved for Hospitalized COVID-19

Save

d Jack Cush, MD

Oct 22, 2020

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Read Article

FDA approved its 1st drug to treat COVID-19 - the antiviral drug Veklury (remdesivir) for for acute care treatment of COVID-19 requiring hospitalization. Approval based on 3 clinical trials showing clinical improvement, but no change in mortality rates. https://t.co/IrA7oKMuGq

Links:

https://bit.ly/35rL5pV

Dr. John Cush RheumNow ( View Tweet)

Oct 22, 2020

Study from NY shows that Death rates from COVID-19 have dropped (in hospitalized pts) from a high of 27% down to 3%. Partly because a younger, healthier are now getting infected, arriving @ hospital w/ less-severe Sxs. Also improved COVID medical care https://t.co/8aFuVHUDjY

Links:

https://bit.ly/35iEZZ6

Dr. John Cush RheumNow ( View Tweet)

Oct 22, 2020

#LTF Listen to Fauci

Dr. John Cush RheumNow ( View Tweet)

Oct 22, 2020

Clinical Trial Boom or Bust in Severe COVID-19

Save

d Jack Cush, MD

Oct 20, 2020

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.

Remdesivir

Read Article

Outpatient Visits Return to Pre-COVID Rates

Save

d Jack Cush, MD

Oct 19, 2020

The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.

Read Article

Pre Print of UK research suggests biomarkers for Severe COVID-19 includes markers of myeloid or endothelial activation; such as D-dimer, EN-RAGE, CXCL10, GM-CSF, IL-6, TNF-α, IL-2, GDF-15, G-CSF, S100A12, https://t.co/Yv6yM4DYmp

Links:

https://bit.ly/3lW1QjE

Dr. John Cush RheumNow ( View Tweet)

Oct 16, 2020

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Save

d Jack Cush, MD

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article

Topics

All News

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

FDA Hearing on COVID-19 Vaccines

Save

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Save

Remdesivir FDA Approved for Hospitalized COVID-19

Save

Clinical Trial Boom or Bust in Severe COVID-19

Save

Outpatient Visits Return to Pre-COVID Rates

Save

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Save

Do you get our email newsletter?

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20) Save

FDA Hearing on COVID-19 Vaccines Save

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20) Save

Remdesivir FDA Approved for Hospitalized COVID-19 Save

Clinical Trial Boom or Bust in Severe COVID-19 Save

Outpatient Visits Return to Pre-COVID Rates Save

RheumNow Podcast – Good Time Charlie…. (10.16.20) Save

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

FDA Hearing on COVID-19 Vaccines

Save

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Save

Remdesivir FDA Approved for Hospitalized COVID-19

Save

Clinical Trial Boom or Bust in Severe COVID-19

Save

Outpatient Visits Return to Pre-COVID Rates

Save

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Save